Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 7, 1999, Pages 1009-1012

  Zhi, Lin ^a   Tegley, Christopher M ^a   Marschke, Keith B ^a   Jones, Todd K ^a  

^a Department of Medicinal Chemistry ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2(1H) PIPERIDINO[3,2 G]QUINOLINONE; 7,8 DIETHYL 4 TRIFLUOROMETHYL 2(1H) PIPERIDINO[3,2 G]QUINOLINONE; ANDROGEN RECEPTOR; ANDROSTANOLONE; ESTROGEN RECEPTOR; GLUCOCORTICOID RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; HORMONE RECEPTOR STIMULATING AGENT; LG 121091; LG 121104; MINERALOCORTICOID RECEPTOR; PROGESTERONE RECEPTOR; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ALKYLATION; ARTICLE; BINDING AFFINITY; CHIRALITY; CYCLIZATION; DOSE RESPONSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION;

ANDROGEN ANTAGONISTS; HUMANS; PIPERIDINES; QUINOLONES; RECEPTORS, ANDROGEN; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 0033526095     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00119-5     Document Type: Article

References (12)

1. 1. Current address: Ontogen Corporation, 2325 Camino Vida Roble, Carlsbad, CA92009.
2. 2. Schellhammer, P. F.; Sharifi, R.; Block, N. L.; Soloway, M. S.; Venner, P. M.; Patterson, A. L.; Sarosdy, M. F.; Vogelzang, N. J.; Schellenger, J. J.; Kolvenbag, G. J. C. M. Urology, 1997, 50 (3), 330.
3. 3. (a) Edwards, J. P.; West, S. J.; Pooley, C. L. F.; Marschke, K. B.; Farmer, L. J.; Jones, T. K. Bioorg. Med. Chem. Lett. 1998, 8, 745.
4. (b) Dalton, J. T.; Mukherjee, A.; Zhu, Z.; Kirkovsky, L.; Miller, D. D. Biochem. Biophy. Res. Comm. 1998, 244, 1.
5. 4. Hamann, L. G.; Higuchi, R. I.; Zhi, L.; Edwards, J. P.; Wang, X. N.; Marschke, K. B.; Kong, J. W.; Farmer, L. J.; Jones, T. K. J. Med. Chem. 1998, 41, 623.
6. 5. Hauser, C. R.; Renolds, G. A. J. Am. Chem. Soc. 1948, 70, 2402.
7. 1H NMR (400 MHz, acetone-d6) 10.67 (bs, 1 H), 7.27 (s, 1 H), 6.52 (s, 1 H), 6.41 (s, 1 H), 6.30 (bs, 1 H), 3.35 (m, 1 H), 2.82 (m, 1 H), 2.71 (dd, J = 16.2, 8.1, 1 H), 1.89 (m, 1 H), 1.60-1.21 (m, 4 H), 1.01 (t, J = 7.5, 3 H) and 0.97 (t, J = 7.5, 3 H).
8. 7. The cross-reactivity profile of 22 and 24 with other steroid receptors is consistent with related series; see ref. 3a and 9.
9. 8. The substituent effects that switch agonist/antagonist activities have been seen in other steroid receptors, e.g. PR see (a) Cook, C. E.; Wani, M. C.; Lee, Y.-W.; Fail, P. A.; and Petrow, V. Life Sciences 1992, 52, 155, and ER see
10. (b) Bowler J.; Lilley, T. J.; Pittam, J. D.; and Wakeling, A. E. Steroids 1989, 54(1), 71.
11. 9. (a) Edwards, J. P.; Higuchi, R. I.; Winn, D.T.; Pooley, C. L. F.; Caferro, T. R.; Hamann, L. G.; Zhi, L.; Marschke, K. M.; Goldman, M. E.; and Jones, T. K. Bioorg. Med. Chem. Lett., 1999, 9, 1003.
12. (b) Hamann, L. G.; Mani, N. S.; Davis, R. L.; Wang, X-N.; Marschke, K. B.; and Jones, T. K. J. Med. Chem. 1999, 42(2), 210.